Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of VX-993 and Metformin
NCT06523595Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VX-993 in pain, sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Metformin in Absence and Presence of VX-993 at Day 14, Area Under the Concentration Versus Time Curve for the Last Measurable Concentration (AUClast) of Metformin at Day 14 and 1 more. Started Jul 2024; status: completed.
02
Drugs
VX-993
03
Conditions
pain
Beyond the preview
Go deeper on NCT06523595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523595.